ALFA Filings
Every announcement, straight from the exchange
Every Zydus Lifesciences other announcement announcement on NSE and BSE, newest first, each with its own page.
Time
7 announcements
Zydus Lifesciences Limited has been assigned an ESG rating of 71 by NSRAL for the financial year 2026. This unsolicited rating reflects the company's sustainability performance.
Zydus Lifesciences Limited submitted the quarterly certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, confirming share dematerialization compliance for the quarter ended September 30, 2026.
Zydus Lifesciences Limited has been assigned an overall ESG rating of 60 by ESG Risk Assessments and Insights Limited (ESGRAIL) based on independent assessment.
Zydus Lifesciences reported a contra trade violation by a designated person under SEBI PIT Regulations. The profit of Rs. 18,797 was transferred to the IEPF.
Zydus Lifesciences received US FDA Priority Review for its Saroglitazar NDA. This regulatory milestone accelerates the potential US launch for Primary Biliary Cholangitis treatment.
Zydus Lifesciences submitted its Annual Secretarial Compliance Report for FY2026. The report noted a minor technical delay in board meeting intimation resulting in total fines of ₹23,600.
Zydus Lifesciences Limited has been assigned an overall ESG rating of 68 by ESGRAIL, an improvement from last year's 66. The rating was prepared independently based on publicly available information. This update reflects the company's ongoing commitment to environmental, social, and governance standards.